Krystal Biotech (KRYS) Net Income towards Common Stockholders (2016 - 2026)

Krystal Biotech has disclosed Net Income towards Common Stockholders across 11 years of filings, most recently posting $55.9 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $55.9 million, up 56.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $225.1 million (up 81.52% YoY), and the FY2025 annual result was $204.8 million, up 129.74% from the prior year.
• Net Income towards Common Stockholders came in at $55.9 million for Q1 2026 at Krystal Biotech, up from $51.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $80.7 million in Q3 2023 to a low of -$50.0 million in Q1 2022.
• The 5-year median for Net Income towards Common Stockholders is $15.6 million (2024), against an average of $13.0 million.
• Across the five-year window, Net Income towards Common Stockholders sank 215.99% in 2022 and soared 3734.01% in 2025, its largest moves.
• Krystal Biotech's Net Income towards Common Stockholders stood at -$32.1 million in 2022, then soared by 127.12% to $8.7 million in 2023, then jumped by 423.62% to $45.5 million in 2024, then rose by 12.93% to $51.4 million in 2025, then advanced by 8.82% to $55.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $55.9 million (Q1 2026), $51.4 million (Q4 2025), and $79.4 million (Q3 2025), per Business Quant data.